Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method

NCT02276768 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain
Cancer
Colonic Disease

Interventions

DRUG: GIC-1001 375 mg TID
DRUG: GIC-1001 500 mg TID
DRUG: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
DRUG: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)
OTHER: Placebo

Sponsor

gicare Pharma Inc.

Collaborators

[object Object]